{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:39:29Z","timestamp":1790995169412,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":383,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jacc.2019.03.501","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T13:58:18Z","timestamp":1560175098000},"page":"2915-2929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"title":["Aspirin for Primary Prevention of Cardiovascular\u00a0Events"],"prefix":"10.1016","volume":"73","author":[{"given":"Hesham K.","family":"Abdelaziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga Venkata K.","family":"Pothineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Megaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Potluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Lai Chin","family":"Kon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert D.","family":"Aronow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Dawn","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawahar L.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2019.03.501_bib1","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Antithrombotic Trialists\u2019 (ATT) Collaboration Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.03.501_bib2","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.jacc.2011.10.824","article-title":"AHA\/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation","volume":"58","author":"Smith","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.03.501_bib3","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2019.03.501_bib4","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.03.501_bib5","article-title":"Contemporary primary prevention aspirin use by cardiovascular disease risk: impact of US Preventive Services Task Force recommendations, 2007\u20132015: a serial, cross-sectional study","volume":"6","author":"Van\u2019t Hof","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2019.03.501_bib6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","article-title":"Randomised trial of prophylactic daily aspirin in British male doctors","volume":"296","author":"Peto","year":"1988","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.jacc.2019.03.501_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing Physicians\u2019 Health Study","volume":"321","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.03.501_bib8","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.03.501_bib9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.03.501_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","article-title":"Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice","volume":"357","author":"de Gaetano","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.03.501_bib11","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A\u00a0randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.03.501_bib12","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.03.501_bib13","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2019.03.501_bib14","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.03.501_bib15","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1001\/jama.2014.15690","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial","volume":"312","author":"Ikeda","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.03.501_bib16","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2019.03.501_bib17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1161\/STR.0b013e3181fcb238","article-title":"Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"42","author":"Goldstein","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2019.03.501_bib18","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2337\/dc10-0555","volume":"33","author":"Pignone","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2019.03.501_bib19","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/CIRCULATIONAHA.116.025760","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial","volume":"135","author":"Saito","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.03.501_bib20","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.03.501_bib21","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.03.501_bib22","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.03.501_bib23","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.03.501_bib24","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","article-title":"Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.03.501_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.03.501_bib26","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2019.03.501_bib27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jacc.2019.03.501_bib28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2019.03.501_bib29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2019.03.501_bib30","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1001\/jama.1992.03490100090033","article-title":"Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14","volume":"268","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.03.501_bib31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10557-018-6802-1","article-title":"Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study)","volume":"32","author":"Goicoechea","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2019.03.501_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090286","article-title":"Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status","volume":"9","author":"Xie","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2019.03.501_bib33","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.amjmed.2011.01.018","article-title":"Effect of aspirin on mortality in the primary prevention of cardiovascular disease","volume":"124","author":"Raju","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2019.03.501_bib34","doi-asserted-by":"crossref","first-page":"804","DOI":"10.7326\/M15-2113","article-title":"Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force","volume":"164","author":"Guirguis-Blake","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2019.03.501_bib35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archinternmed.2011.628","article-title":"Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials","volume":"172","author":"Seshasai","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2019.03.501_bib36","doi-asserted-by":"crossref","first-page":"826","DOI":"10.7326\/M15-2112","article-title":"Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force","volume":"164","author":"Whitlock","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2019.03.501_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2017.04.052","article-title":"Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015","volume":"70","author":"Roth","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.03.501_bib38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1745-6215-8-21","volume":"8","author":"De Berardis","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.jacc.2019.03.501_bib39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ahj.2011.04.006","article-title":"Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials","volume":"162","author":"Berger","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2019.03.501_bib40","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.thromres.2011.10.036","article-title":"Antiplatelet therapy: controversial aspects","volume":"129","author":"Coccheri","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2019.03.501_bib41","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/ehp097","article-title":"COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment","volume":"30","author":"Pulcinelli","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.03.501_bib42","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/09537104.2011.634932","article-title":"Platelet reactivity in type 2 diabetes mellitus: A comparative analysis with survivors of myocardial infarction and the role of glycaemic control","volume":"23","author":"Mylotte","year":"2012","journal-title":"Platelets"},{"key":"10.1016\/j.jacc.2019.03.501_bib43","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1016\/j.thromres.2010.03.013","article-title":"Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus","volume":"126","author":"Mortensen","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2019.03.501_bib44","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1001\/jama.2012.5034","article-title":"Association of aspirin use with major bleeding in patients with and without diabetes","volume":"307","author":"De Berardis","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.03.501_bib45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1741-7015-4-22","article-title":"Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications","volume":"4","author":"Hern\u00e1ndez-D\u00edaz","year":"2006","journal-title":"BMC Med"},{"key":"10.1016\/j.jacc.2019.03.501_bib46","doi-asserted-by":"crossref","first-page":"814","DOI":"10.7326\/M15-2117","article-title":"Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force","volume":"164","author":"Chubak","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2019.03.501_bib47","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M15-2129","article-title":"Aspirin for the primary prevention of cardiovascular disease and colorectal cancer: a decision analysis for the U.S. Preventive Services Task Force","volume":"164","author":"Dehmer","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2019.03.501_bib48","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1016\/j.jacc.2016.02.055","article-title":"Accuracy of the atherosclerotic cardiovascular risk equation in a large contemporary, multiethnic population","volume":"67","author":"Rana","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.03.501_bib49","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/apt.12240","article-title":"The\u00a0aspirin cardiovascular\/gastrointestinal risk calculator--a tool to aid clinicians in practice","volume":"37","author":"Lanas","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jacc.2019.03.501_bib50","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.03.501_bib51","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/eurheartj\/ehy813","article-title":"Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials","volume":"40","author":"Mahmoud","year":"2019","journal-title":"Eur Heart J"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719348582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719348582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:22:38Z","timestamp":1760016158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109719348582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":51,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0735109719348582"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2019.03.501","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin for Primary Prevention of Cardiovascular\u00a0Events","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2019.03.501","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}